Certified Pediatric Nurse Practitioner - Primary Care Free Sample Questions

According to the Bright Futures/AAP Recommendations for Preventive Pediatric Health Care and the AAP clinical practice guideline on hyperbilirubinemia, any newborn discharged less than 48 hours after delivery must be evaluated in the outpatient setting within 48 hours of discharge (typically corresponding to 3 to 5 days of age). The primary focus of this visit is to assess breastfeeding latch and milk transfer, percentage of weight loss from birth, hydration status (voiding and stooling patterns), and clinical or transcutaneous/serum bilirubin levels as bilirubin peaks between days 3 and 5 of life. Waiting until 1 or 2 weeks of age risks missing severe hyperbilirubinemia (kernicterus) or hypernatremic dehydration. Critical congenital heart disease (CCHD) screening via pulse oximetry is completed after 24 hours of life prior to hospital discharge rather than deferred to 1 week.

Current AAP and Bright Futures oral health guidelines recommend that caregivers brush a child's teeth twice daily (after breakfast and before bedtime) with fluoridated toothpaste as soon as the first primary tooth erupts. For children younger than 3 years of age, the proper age-based dosage is a smear or grain-of-rice-sized amount (approximately 0.1 mg of fluoride), which provides topical caries protection while minimizing the risk of fluorosis if swallowed. At age 3 through 6 years, the dosage increases to a pea-sized amount (approximately 0.25 mg of fluoride). Non-fluoridated toothpaste does not prevent early childhood caries, and systemic fluoride supplementation is reserved only for children aged 6 months and older whose primary drinking water source is deficient in fluoride (<0.6 ppm).

Honey (both raw and pasteurized/cooked) must be strictly avoided before 12 months of age because the infant gastrointestinal tract lacks sufficient acidity and mature flora to inhibit Clostridium botulinum spore germination and toxin production. Whole cow's milk must also be avoided as a main drink before 12 months because it is low in bioavailable iron, presents a high renal solute load, and can induce occult gastrointestinal blood loss. Conversely, delaying allergenic foods (peanut, egg) increases allergy risk, and 100% fruit juice is not recommended before 12 months of age.

By 6 months of age, a full-term infant's endogenous transplacental iron stores are largely depleted, and human milk alone does not provide sufficient iron or zinc to meet rapid growth demands; therefore, introducing bioavailable iron- and zinc-rich foods (such as puréed meats or iron-fortified infant cereal) is a top nutritional priority.

According to the AAP Red Book and CDC Advisory Committee on Immunization Practices (ACIP) guidelines, high-dose intravenous immunoglobulin (IVIG, 2 g/kg) administered for Kawasaki disease contains circulating maternal/donor antibodies that neutralize live-attenuated parenteral viral vaccines (MMR and varicella), preventing adequate viral replication and protective seroconversion. Therefore, MMR and varicella vaccines must be deferred for 11 months following a 2 g/kg IVIG dose (unless a community measles outbreak warrants earlier vaccination followed by revaccination at >=11 months post-IVIG). Inactivated, toxoid, and conjugate vaccines (such as DTaP and Hib) are not significantly affected by circulating antibody and should be administered on schedule today.

A history of intussusception (regardless of whether it occurred following a previous rotavirus vaccine dose or spontaneously) is an absolute contraindication to the administration of any subsequent doses of rotavirus vaccine (both RV5 and RV1) because postlicensure surveillance demonstrates a small but statistically significant increased risk of intussusception, particularly within 1 to 21 days after the first or second dose. Switching between pentavalent and monovalent formulations is likewise contraindicated. However, the history of intussusception has no bearing on parenteral inactivated/conjugate vaccines, so the second doses of DTaP, IPV, Hib, and PCV should be administered on schedule.

When addressing vaccine hesitancy after an initial presumptive announcement, the PNP should use motivational interviewing principles: validate the parent's desire to protect their child, ask permission to share scientific information, and maintain a strong, unequivocal recommendation focused on cancer prevention (specifically oropharyngeal, anal, penile, and cervical cancers). Immunologically, preadolescents aged 9 to 14 years mount a substantially stronger geometric mean antibody titer response to the 9-valent HPV vaccine than older adolescents and young adults. Because of this robust immune response, immunocompetent patients who initiate the series before their 15th birthday require only a 2-dose schedule (administered at 0 and 6–12 months), whereas initiating the series at age 15 years or older requires a 3-dose schedule (0, 1–2, and 6 months). Furthermore, prophylactic HPV vaccination is most effective when completed well before any sexual contact occurs.